

ASX ANNOUNCEMENT

Benitec to advance drug resistant lung cancer program into European clinical trial

- **Benitec commits to progressing gene silencing therapeutic Tribetarna™, its non-small cell lung cancer (NSCLC) program, toward European based Phase I/IIa clinical trial**
- **Decision follows solid proof of principle data obtained in April 2013**
- **Trial to be managed by European based Clinical Research Organisation, Clinical Trials Group, with broad clinical trial experience**

Sydney, Australia, 3 June 2013: Benitec Biopharma Ltd (ASX: BLT) today announced it has committed to moving its non-small cell lung cancer (NSCLC) therapeutic, Tribetarna™, into the clinic, following positive proof-of-principle data obtained in collaboration with the Children's Cancer Institute Australia at the University of New South Wales and announced in April 2013.

Benitec has agreed to use European-based clinical research organisation Clinical Trials Group (CTGCRO) to manage the initial clinical development of Tribetarna™, and the proposed Phase I/IIa clinical trial is planned to commence in Q4 CY14.

CTGCRO has broad experience in conducting clinical trials and preparing regulatory submissions to FDA and European standards. The company has conducted a number of clinical trials supporting treatments for Cancer, Multiple Sclerosis and Parkinson's disease.

The decision to progress Tribetarna™ into clinical development will be subject to obtaining appropriate funding. This funding, together with the planned US-based Phase I/IIa clinical trial in hepatitis C (HCV) patients, forms part of the Company's capital management strategies.

Benitec's CEO Dr Peter French commented on the announcement, saying: "We are delighted to be now advancing Tribetarna™ into the clinic, and together with existing plans to commence a Phase I/IIa trial in HCV patients in the second half of this year, demonstrates the company's transition from a preclinical to clinical stage company. We anticipate that achieving clinical success of ddRNAi-based therapeutics in HCV and drug resistant lung cancer will significantly enhance the value of the company for its shareholders."



About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.

For more information please contact: Carl Stubbings | Chief Business Officer
Phone: +61 (02) 9555 6986 | cstubbings@benitec.com | www.benitec.com